AEGLEA BIOTHERAPEUTICS, INC. (NASDAQ:AGLE) Files An 8-K Regulation FD Disclosure

AEGLEA BIOTHERAPEUTICS, INC. (NASDAQ:AGLE) Files An 8-K Regulation FD Disclosure

Story continues below

Item 7.01 Regulation FD Disclosure.

Aeglea BioTherapeutics, Inc. (the Company) will present the
information in the presentation poster attached hereto as Exhibit
99.1 on March 23, 2017 at the 2017 American College of Medical
Genetics and Genomics Annual Clinical Genetics Meeting, being
held March 21-25, 2017 in Phoenix, Arizona. The presentation
poster will also be available on the Companys website in the
Events Presentations section at www.aegleabio.com.

The information furnished with this report, including Exhibit
99.1, shall not be deemed filed for purposes of Section 18 of the
Securities Exchange Act of 1934, as amended (Exchange Act), or
otherwise subject to the liabilities of that section, nor shall
it be deemed incorporated by reference into any other filing
under the Securities Act of 1933, as amended, or the Exchange
Act, except as expressly set forth by specific reference in such
a filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit Number

Description

99.1

Presentation Poster


About AEGLEA BIOTHERAPEUTICS, INC. (NASDAQ:AGLE)

Aeglea BioTherapeutics, Inc. is a biotechnology company, which is engaged in the development of enzyme-based therapeutics in the field of amino acid metabolism to treat inborn errors of metabolism (IEM) and cancer. The Company’s product pipeline includes AEB1102, AEB3103, AEB2109 and AEB4104. Its lead product candidate, AEB1102, is engineered to degrade the amino acid arginine and is being developed to treat over two extremes of arginine metabolism, including arginine excess in patients with Arginase I deficiency, an IEM, as well as some cancers, which have shown to have a metabolic dependence on arginine. AEB1102 reduces blood arginine levels in nonclinical and oncology clinical studies. AEB3103 targets the degradation of the amino acid cysteine/cystine. AEB2109 targets the degradation of the amino acid methionine. AEB4104 targets the reduction of elevated levels of the amino acid homocystine associated with the IEM classical homocystinuria.

AEGLEA BIOTHERAPEUTICS, INC. (NASDAQ:AGLE) Recent Trading Information

AEGLEA BIOTHERAPEUTICS, INC. (NASDAQ:AGLE) closed its last trading session 00.00 at 7.71 with 30,101 shares trading hands.

An ad to help with our costs